IRF7 Antikörper (Alexa Fluor 488)
-
- Target Alle IRF7 Antikörper anzeigen
- IRF7 (Interferon Regulatory Factor 7 (IRF7))
-
Reaktivität
- Human
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser IRF7 Antikörper ist konjugiert mit Alexa Fluor 488
-
Applikation
- Intracellular Staining (ICS)
- Marke
- BD Phosflow™
- Aufreinigung
- The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
- Immunogen
- Human IRF-7 Recombinant Protein
- Klon
- K40-321
- Isotyp
- IgG1 kappa
- Top Product
- Discover our top product IRF7 Primärantikörper
-
-
- Kommentare
-
BALB/c
- Probenmenge
- 20 μL
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
- Aqueous buffered solution containing BSA and ≤0.09 % sodium azide.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C
- Informationen zur Lagerung
- Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The antibody was conjugated to Alexa Fluor® 488 under optimum conditions, and unreacted Alexa Fluor® 488 was removed.
-
-
Triggering the interferon antiviral response through an IKK-related pathway." in: Science (New York, N.Y.), Vol. 300, Issue 5622, pp. 1148-51, (2003) (PubMed).
: "
-
Triggering the interferon antiviral response through an IKK-related pathway." in: Science (New York, N.Y.), Vol. 300, Issue 5622, pp. 1148-51, (2003) (PubMed).
-
- Target
- IRF7 (Interferon Regulatory Factor 7 (IRF7))
- Andere Bezeichnung
- IRF-7 (IRF7 Produkte)
- Synonyme
- wu:fl24c03 antikoerper, zgc:66043 antikoerper, zgc:77947 antikoerper, IRF7 antikoerper, irf7 antikoerper, IRF-7H antikoerper, IRF7A antikoerper, IRF7B antikoerper, IRF7C antikoerper, IRF7H antikoerper, interferon regulatory factor 7 antikoerper, irf7 antikoerper, IRF7 antikoerper, Irf7 antikoerper
- Hintergrund
- Interferon regulatory factor 7 (IRF-7) is a transcription factor that regulates anti-viral defenses by controlling the induction of type-I interferon (IFN) responses. IRF-7 expression is induced in lymphoid cells by virus infection, as well as by IFN, lipopolysaccharide, and TNF-a. IRF-7 responses are initiated by Toll-like receptors (TLR) or the cytoplasmic protein retinoic acid inducible gene I (RIG-I). Upon TLR activation, it forms cytoplasmic complexes with MyD88, an adaptor in the TLR signaling pathways. The TLR-dependent and RIG-I-dependent pathways activate kinases, such as IKK-e and TBK1, that phosphorylate IRF-7 and induce movement of IRF-7-containing complexes to the nucleus, where it preferentially activates IFN-a promoters. The K40-321 monoclonal antibody recognizes human IRF-7, regardless of phosphorylation status. Our in-house testing is performed on a cell line that has been co-transfected with TBK1 and IRF-7. Phosphorylation of IRF-7 in the transfectants requires virus infection or over-expression of a signaling molecule of the RIG-I pathway, such as TBK1. Phosphorylation of endogenous IRF-7 in untransfected cells has not yet been detected. We confirmed that mAb K40-321 does not cross-react with TBK1 by Western blot analysis using the purified antibody.
- Pathways
- TLR Signalweg, Activation of Innate immune Response, Hepatitis C, Toll-Like Receptors Cascades, Autophagie
-